Moving T1D forward through advocacy
Breakthrough T1D Chief Global Advocacy Officer Lynn Starr discusses how type 1 diabetes advocacy drives our mission progress forward...faster.
Transforming Lives, One Step At a Time
Meet three Walk teams that are changing the lives of people with type 1 diabetes, one step at a time.
Putting the Foxes in Charge of the Henhouse: The Dramatic Race to Develop an Artificial Pancreas
The true story of how artificial pancreas systems moved from an idea to a therapy, improving the lives of millions with type 1 diabetes.
Meet Alecia Wesner, a hero for T1D clinical trials
Since 2014, Alecia Wesner has participated in numerous T1D clinical trials, many of which were early artificial pancreas system trials.
Breakthrough T1D Mourns Tragic, Sudden Loss of Five Ride Champions
The leadership, staff, and volunteers of Breakthrough T1D mourn the recent loss of five Ride champions.
Meet Liz Walsh, a hero for pregnancy with T1D
Thanks to advancements in type 1 diabetes treatment and care, Liz Walsh had a complication-free pregnancy with T1D.
Vertex launches pivotal trial for stem-cell derived islet therapy
Vertex announced the first stem cell-derived islet therapy is entering a phase 3 clinical trial for type 1 diabetes.
Fact-checking myths and misconceptions about type 1 diabetes
We take a look at some of the most common misconceptions about T1D and set the record straight!
FDA Advisory Committee does not recommend that sotagliflozin receive approval for glucose lowering in adults with type 1 diabetes (T1D) and Chronic Kidney Disease (CKD)
Update – November 22, 2024 This morning, Lexicon Pharmaceuticals, Inc. (Lexicon) announced they received a “deficiencies preclude discussion” letter from the FDA regarding this drug application. The FDA is not approving sotagliflozin for use in glucose control in people with T1D and CKD and there will be no further discussion in regards to this application. […]
Novel way to protect transplanted cells shows promise
A novel immune therapy called tegoprubart made by Eledon Pharmaceuticals and being tested in kidney transplant patients has the potential to help beta cell transplants survive in people with type 1 diabetes (T1D) with fewer side effects. The first data from this Breakthrough T1D-funded study suggests it does. The study was presented at the 5th […]
